View Older Stories
-
William Blair Updates Analyst Conviction List for June 2026, 6 Adds & 5 Removals
-
Guardant Health (GH) Reiterated at Buy by Stifel on Positive KOL Comments
-
Guardant Health (GH) PT Raised to $160 at BTIG, Second Day in a Row
-
Guardant Health (GH) PT Raised to $155 at BTIG
-
TD Cowen Reiterates Buy Rating on Guardant Health (GH) Following G360 Liquid FDA Approval
-
Guardant Health (GH) Misses Q1 EPS by 4c, provides guidance
-
Guardant Health partners with Nuvalent for cancer diagnostics development
-
Canaccord on Guardant Health (GH): 'not concerned by CMO resignation'
-
Barclays: Life science insiders sold $187M in stock during first quarter
-
Piper Sandler: 'We are buyers of Guardant Health (GH)'
-
'Guardant Health (GH) is our top growth idea'; PT Lowered to $120 at TD Cowen
-
Canaccord Reiterates Buy Rating on Guardant Health (GH)
-
Citi Adjusts Catalyst Watch List
-
Wells Fargo Lays Out Q2 2026 Tactical Idea List Names
-
Verana Health partners with Guardant Health for precision medicine data
-
Guardant Health (GH) PT Raised to $130 at Stifel on Upside Drivers Ahead
-
Guardant Health (GH) PT Raised to $135 at Canaccord Genuity
-
Guardant Health (GH) Tops Q4 EPS by 27c; offers guidance
-
Baird Starts Guardant Health (GH) at Outperform
-
Guardant Health blood test shows improved cancer recurrence prediction
-
Canaccord Genuity Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health posts 39% revenue growth in fourth quarter
-
Guardant Health (GH) PT Raised to $120 at Stifel: Poised for Solid Volume, ASP Growth
-
Guardant Health (GH) PT Raised to $130 at Jefferies
-
BTIG: 'we name GH and WGS as 2026 Top Picks'
-
Guardant Health launches liquid biopsy testing at Italian hospital
-
Guardant Health expands blood test for late-stage cancer monitoring
-
Guardant Health (GH) PT Raised to $115 at Raymond James
-
Guardant Health (GH) PT Raised to $100 at TD Cowen
-
Guardant Health (GH) PT Raised to $100 at BofA Securities
-
Guardant Health (GH) PT Raised to $100 at Canaccord Genuity
-
Guardant Health (GH) PT Raised to $90 at Wolfe Research
-
Guardant Health (GH) PT Raised to $100 at BTIG, Top Pick
-
Guardant Health (GH) PT Raised to $100 at Citi
-
Nephron Upgrades Guardant Health (GH) to Hold
-
Guardant Health (GH) Tops Q3 EPS by 40c, Offers Guidance
-
Guardant Health partners with Zephyr AI for cancer biomarker research
-
Bernstein 'Positive' on Guardant Health (GH) Post 2025 Investor Day
-
Guardant Health (GH) Raised to PT $70 at JP Morgan
-
Guardant Health (GH) PT Raised to $67 at Guggenheim
-
Guardant Health (GH) PT Raised to $72 at TD Cowen
-
Guardant Health (GH) PT Raised to $70 at Mizuho
-
Canaccord Genuity Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health (GH) PT Raised to $75 at Leerink Partners
-
Wolfe Research Upgrades Guardant Health (GH) to Outperform, 'We have been wrong on GH over the past year'
-
Guardant Health (GH) PT Raised to $70 at Stifel
-
Guardant Health (GH) PT Raised to $80 at BTIG
-
UBS Reiterates Buy Rating on Guardant Health (GH)
-
Canaccord Genuity Reiterates Buy Rating on Guardant Health (GH)
-
BTIG Reiterates Top Pick on Guardant Health (GH)

